PULM

Pulmatrix, Inc. (NASDAQ:PULM) is a clinical-stage biotechnology company founded in 2003 and headquartered in Lexington, Massachusetts. The company went public in March 2014 and specializes in developing inhaled therapies for respiratory and other diseases with significant unmet medical needs. Pulmatrix focuses on leveraging its proprietary drug delivery platform to create innovative treatments that can be administered directly to the lungs through inhalation.